Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials

Annals of the Rheumatic Diseases

Volumn 71, Issue 11, 2012, Pages 1833-1838

  Manzi, Susan ^a   Sánchez Guerrero, Jorge ^b   Merrill, Joan T ^c   Furie, Richard ^d   Gladman, Dafna ^e   Navarra, Sandra V ^f   Ginzler, Ellen M ^g   D'Cruz, David P ^h   Doria, Andrea ⁱ   Cooper, Simon ^j   Zhong, Z John ^j   Hough, Douglas ^j   Freimuth, William ^j   Petri, Michelle A ^k  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d North Shore LIJ Health System ^*  (United States)

^e TORONTO WESTERN HOSPITAL   (Canada)

^f UNIVERSITY OF SANTO TOMAS HOSPITAL   (Philippines)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

^h ST THOMAS HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j GLAXOSMITHKLINE   (United States)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BELIMUMAB; CORTICOSTEROID; CYCLOSPORIN; DOUBLE STRANDED DNA ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; ARTICLE; BRITISH ISLES LUPUS ASSESSMENT GROUP; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOPATHOLOGY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL DISEASE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAFETY OF ESTROGENS IN LUPUS NATIONAL ASSESSMENT SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX; SCORING SYSTEM; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL; B-CELL ACTIVATING FACTOR; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84867398973     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200831     Document Type: Article

References (13)

1. Lau CS, Mak A. The socioeconomic burden of SLE. Nat Rev Rheumatol 2009;5:400-4.
2. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39. (Pubitemid 351397092)
3. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48:3253-65. (Pubitemid 37409340)
4. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58:2453-9.
5. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
6. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
7. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 15 February 2012 doi:10.1136/annrheumdis-2011-200937
8. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51.
9. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8. (Pubitemid 41785892)
10. Isenberg DA, Gordon C. From BILAG to BLIPS - disease activity assessment in lupus past, present and future. Lupus 2000;9:651-4. (Pubitemid 32011789)
11. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
12. Touma Z, Urowitz MB, Ibañez D, et al. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus 2011;20:67-70.
13. Stohl W, Jacob N, Guo S, et al. Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity. Arthritis Rheum 2010;62:2432-42.